Cansino Biologics Stock Current Valuation
| 688185 Stock | 61.23 0.13 0.21% |
Valuation analysis of Cansino Biologics helps investors to measure Cansino Biologics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Cansino Biologics' Cash is projected to increase significantly based on the last few years of reporting. The current year's Total Cash From Financing Activities is expected to grow to about 1.6 B, whereas Change In Cash is projected to grow to (735.9 M). Fundamental drivers impacting Cansino Biologics' valuation include:
Price Book 3.1066 | Enterprise Value 9.7 B | Enterprise Value Ebitda (3.94) | Price Sales 14.2891 | Enterprise Value Revenue 15.972 |
Fairly Valued
Today
Please note that Cansino Biologics' price fluctuation is very steady at this time. Calculation of the real value of Cansino Biologics is based on 3 months time horizon. Increasing Cansino Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cansino Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cansino Stock. However, Cansino Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 61.23 | Real 58.99 | Hype 61.19 |
The real value of Cansino Stock, also known as its intrinsic value, is the underlying worth of Cansino Biologics Company, which is reflected in its stock price. It is based on Cansino Biologics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cansino Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Cansino Biologics helps investors to forecast how Cansino stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cansino Biologics more accurately as focusing exclusively on Cansino Biologics' fundamentals will not take into account other important factors: Cansino Biologics Company Current Valuation Analysis
Cansino Biologics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Cansino Biologics Current Valuation | 9.74 B |
Most of Cansino Biologics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cansino Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Cansino Biologics has a Current Valuation of 9.74 B. This is 32.22% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all China stocks is 41.44% higher than that of the company.
Cansino Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cansino Biologics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cansino Biologics could also be used in its relative valuation, which is a method of valuing Cansino Biologics by comparing valuation metrics of similar companies.Cansino Biologics is currently under evaluation in current valuation category among its peers.
Cansino Fundamentals
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0792 | ||||
| Profit Margin | (0.96) % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 9.74 B | ||||
| Shares Outstanding | 114.78 M | ||||
| Shares Owned By Insiders | 62.90 % | ||||
| Shares Owned By Institutions | 3.68 % | ||||
| Price To Book | 3.11 X | ||||
| Price To Sales | 14.29 X | ||||
| Revenue | 345.18 M | ||||
| Gross Profit | (183.71 M) | ||||
| EBITDA | (829.73 M) | ||||
| Net Income | (1.45 B) | ||||
| Total Debt | 1.39 B | ||||
| Book Value Per Share | 20.58 X | ||||
| Cash Flow From Operations | (916.25 M) | ||||
| Earnings Per Share | (3.51) X | ||||
| Target Price | 61.34 | ||||
| Number Of Employees | 1.49 K | ||||
| Beta | 0.49 | ||||
| Market Capitalization | 10.7 B | ||||
| Total Asset | 9.32 B | ||||
| Retained Earnings | (1.56 B) | ||||
| Working Capital | 2.59 B | ||||
| Net Asset | 9.32 B |
About Cansino Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cansino Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cansino Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cansino Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Cansino Stock
Cansino Biologics financial ratios help investors to determine whether Cansino Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cansino with respect to the benefits of owning Cansino Biologics security.